Uterine fibroids in premenopausal women
https://doi.org/10.21518/2079-701X-2019-13-123-128
Abstract
Uterine fibroids are one of the commonest benign pelvic tumours with an estimated incidence of 20–40% in women during their reproductive years. Incidence rates for uterine fibroid diagnoses were highest in premenopausal age. The gynecologists are frequently faced with need for the administration of menopausal hormone therapy (MHT) in this group of patients with the onset of symptoms associated with estrogen deficiency; however, uterine fibroids represent a relative contraindication for the administration of MHT. In the present paper, we point out the need for conservative therapy of uterine fibroids in premenopausal patients to prepare for the administration of MHT. The paper reflects the efficacy of the drug treatment of uterine fibroids using antigestagens (gynestril).
About the Authors
Yu. E. Dobrokhotova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Yuliya E. Dobrokhotova, Dr. of Sci. (Med.), Professor, Head of Chair for Obstetrics and Gynecology, Department of General Medicine
1, Ostrovityanova Street, Moscow, 117997
I. Yu. Ilina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Irina Yu. Ilina, Dr. of Sci. (Med.), Professor, Chair for Obstetrics and Gynecology, Department of General Medicine
1, Ostrovityanova Street, Moscow, 117997
References
1. Adamyan L.V., Andreeva E.N., Artymuk N.V., Belotserkovtseva L.D., Bezhenar V.F. Uterine fibroids: diagnosis, treatment and rehabilitation. Clinical guidelines for the patient management. (In Russ.) Moscow. 2015:333-335. Available at: https://stopmyoma.ru/wp-content/uploads/2017/09/%D0%9C%D0%B8%D0%BE%D0%BC%D0%B0.%D0%9F%D1%80%D0%BE%D1%82%D0%BE%D0%BA%D0%BE%D0%BB-%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F-2015.pdf.
2. Donnez J., Vazques F., Tomaszewski J., Nouri K., Bouchard P., Fauser B.C., Barlow D.H., Palacios S., Donnez O., Bestel E., Osterloh I., Loumaye E. Long-term treatment of uterine fibroids with uliprista acetate. Fertility and sterility. 2014;101(6):1565-1573. doi: 10.1016/j.fertnstert.2014.02.008.
3. Saveleva G.M., Sukhikh G.T., Radzinskiy V.E. (ed.) National guideline. Gynecology. М.: GEOTARMedia. 2017. 1063 p. Available at: http://www.rosmedlib.ru/book/ISBN9785970441527.html.
4. Kambolova O.T., L. Balios V., Ivanov I.S., Agnaeva N.Z. Experience of using derivatives of squalene in patients with uterine myoma in perimenopau indoor-age period. Vestnik Rossiyskogo Nauchnogo Tsentra Rentgenoradiologii = Russian Scientific Center of Roentgenoradiology. 2010;(10):4-6. (In Russ.) Available at: http://vestnik.rncrr.ru/vestnik/v10/papers/kamb_v10.htm.
5. Kichigin O.V., Arestova I.M., Zanko Y.V. Risk factors of hysteromyoma development and quality of life of patients operated in connection with hysteromyoma. Okhrana materinstva i detstva = Maternal and Child Health. 2013;2(22):36-41. (In Russ.) Available at: https://elib.vsmu.by/handle/123/5331.
6. Pansky M., Cowan B.D., Frank M., Hampton H.L., Zimberg S. Laparoscopically assisted uterine fibroid cryoablation. Am J Obstet Gynecol. 2009;201(6):571-577. doi: 10.1016/j.ajog.2009.06.028.
7. Tetelyutina F.K., Tolstolutskaya E.A., Solovieva M.E., Klestov K.B., Mejtis O.I. The results of embolization of uterine arteries at the treatment of patients with hysteromyoma Medicinskij al’manah = Medical Almanac. 2010;(3):91-92. (In Russ.) Available at: https://cyberleninka.ru/article/v/differentsirovannyypodhodk-lecheniyu-miomy-matki.
8. Tikhomirov A.L., Oleynik Ch.G. A differentiated approach to treatment of patients with uterine myoma. Voprosy ginekologii, akusherstva i perinatologii = Gynecology, Obstetrics and Perinatology 2008;7(3):74-81. (In Russ.) Available3: https://elibrary.ru/item.asp?id=11031299.
9. Oboskalova T.A., Koval M.V. Influence of Menopausal Hormone Therapy on uterine myoma in menopausal women. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal. 2017:6(150):5-9. (In Russ.) Available at: https://elibrary.ru/item.asp?id=29827416.
10. Yoldemir T. Fertility in midlife women. Climacteric. 2016;19(3):240-246. doi: 10.3109/13697137.2016.1164133.
11. Bateson D., McNamee K. Perimenopausal contraception: A practice-based approach. Aust Fam Physician. 2017;46(6):372-377. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=Bateson+D.%2C+McNamee+K.+Perimenopausal+contraception%3A+A+practice-based+approach.-+Aust.Fam.Physician.
12. Smetnik V.P., Sukhikh G.T. (ed.) Menopausal hormone therapy and preserving the mature women’s health. Clinical guidelines (protocols). Moscow. 2014. 57 p. Available at:: https://minzdrav.gov-murman.ru/activities/akusherstvo/poryadki/menopauza.pdf.
13. Mejevitinova E., Dovletkhanova E., Ledina A. Hormonal replacement therapy in treatment for climacteric syndrome. Vrach = The Doctor. 2011;(1):21-24. Available at: https://elibrary.ru/item.asp?id=15590198.
14. Graham J.D., Hanson A.R., Croft A.J., Fox A.H., Clarke C.L. Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci. The FASEB Journal. 2009;23(2):546556. doi: 10.1096/fj.08-113639.
15. Dobrokhotova Yu.E., lyina I.Yu., Goncharov I.Yu. Uterine myoma. Non-surgical treatment. RMZH. Mat’ i ditya = RMJ. 2018;2(I):3-6. (In Russ.) Available at: https://www.rmj.ru/articles/ginekologiya/Mioma_matki_Bezoperacionnoe_lechenie/#ixzz5xiAGc1Yz.
Review
For citations:
Dobrokhotova YE, Ilina IY. Uterine fibroids in premenopausal women. Meditsinskiy sovet = Medical Council. 2019;(13):123-128. (In Russ.) https://doi.org/10.21518/2079-701X-2019-13-123-128
Views:
1071
Email this article 